We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > durvalumab

News List

FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer americanpharmaceuticalreview
April 06, 2020
The Food and Drug Administration (FDA) has approved durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Durvalumab improves survival of non-small cell lung cancer patients europeanpharmaceuticalreview
April 18, 2019
Moffitt researchers conducted a Phase III trial which found durvalumab to increase the survival of patients with non-small cell lung cancer…
AZ’ Imfinzi reduces risk of death by 32% in stage III NSCLC pharmatimes
September 27, 2018
AstraZeneca says Imfinzi is the first immunotherapy to show significant overall survival in a curative lung cancer treatment setting.